In the United Kingdom, tirzepatide has only one name - “Mounjaro” - and it’s prescribed for the treatment of weight loss and diabetes. But in the US the same drug is named “Zepbound” for weight loss and “Mounjaro” for diabetes. Two different names for the same weight loss drug? If this sounds familiar, it’s because it is. For Mounjaro and Zepbound read Ozempic and Wegovy. What are these drugs and why do they have different names?
If you need to remember just one thing to answer the question "What is Zepbound?", it is that in the UK there is only one version of Eli Lilly’s blockbuster drug, Tirzepatide. And that’s Mounjaro. It is available in the UK for sale through private companies, such as CheqUp, for the treatment of weight loss and diabetes, and is available for the treatment of diabetes on the NHS. However, given the crossover in media between the UK and the United States, it’s worth understanding that tirzepatide for weight loss has a different name in the US.
Simply, Zepbound and Mounjaro are two brand names which refer to the same drug, tirzepatide.
Tirzepatide targets two hormones in our body which play a crucial role in regulating blood sugar levels and appetite. By mimicking the natural action of our bodies, tirzepatide not only help lower blood sugar levels in people with diabetes but also contribute to weight loss by reducing appetite and food intake.
In the United States and other countries, tirzepatide is known as “Zepbound” for the treatment of weight management and “Mounjaro” for the treatment of diabetes.
From a diabetes management standpoint, Mounjaro has shown promise in helping patients achieve better glycemic control. Clinical trials have highlighted its effectiveness in lowering A1C levels, a key indicator of blood sugar management over time. Patients using Mounjaro for their diabetes treatment have also reported an added benefit of weight loss, making it an attractive option for those looking to manage both their diabetes and weight.
On the flip side, Zepbound, much like Wegovy derived from Ozempic, is positioned in the market primarily as a weight management solution in the United States. Despite being pharmacologically identical to Mounjaro, Zepbound is dosed and marketed differently, focusing on its capacity to aid in significant weight reduction. Clinical trials supporting Zepbound’s approval for weight management showcased substantial weight loss in participants, further cementing GLP-1 receptor agonists' role in obesity treatment.
The parallel between Zepbound/Mounjaro and Ozempic/Wegovy is striking.
Ozempic, initially approved for managing diabetes, shares the same active ingredient as Wegovy, which is approved for weight management. The key difference lies in the dosing and the target audience, with Wegovy being prescribed at higher doses specifically for those looking to lose weight. This strategic bifurcation allows pharmaceutical companies to address two burgeoning health crises with a single molecule, maximizing the therapeutic potential of their discovery.
Clinical trials have been pivotal in demonstrating the efficacy of these medications. For instance, Mounjaro's phase 3 trials for diabetes management showed not only significant reductions in A1C levels but also noted weight loss as a side effect. Similarly, trials for Zepbound in the context of weight management have reported average weight losses of up to 26% of body weight in patients, offering a new hope for individuals struggling with weight issues.
In the United Kingdom, tirzepatide has only one name - “Mounjaro” - and it’s prescribed for the treatment of weight loss and diabetes. But in the US the same drug is named “Zepbound” for weight loss and “Mounjaro” for diabetes. Two different names for the same weight loss drug? If this sounds familiar, it’s because it is. For Mounjaro and Zepbound read Ozempic and Wegovy. What are these drugs and why do they have different names?
If you need to remember just one thing to answer the question "What is Zepbound?", it is that in the UK there is only one version of Eli Lilly’s blockbuster drug, Tirzepatide. And that’s Mounjaro. It is available in the UK for sale through private companies, such as CheqUp, for the treatment of weight loss and diabetes, and is available for the treatment of diabetes on the NHS. However, given the crossover in media between the UK and the United States, it’s worth understanding that tirzepatide for weight loss has a different name in the US.
Simply, Zepbound and Mounjaro are two brand names which refer to the same drug, tirzepatide.
Tirzepatide targets two hormones in our body which play a crucial role in regulating blood sugar levels and appetite. By mimicking the natural action of our bodies, tirzepatide not only help lower blood sugar levels in people with diabetes but also contribute to weight loss by reducing appetite and food intake.
In the United States and other countries, tirzepatide is known as “Zepbound” for the treatment of weight management and “Mounjaro” for the treatment of diabetes.
From a diabetes management standpoint, Mounjaro has shown promise in helping patients achieve better glycemic control. Clinical trials have highlighted its effectiveness in lowering A1C levels, a key indicator of blood sugar management over time. Patients using Mounjaro for their diabetes treatment have also reported an added benefit of weight loss, making it an attractive option for those looking to manage both their diabetes and weight.
On the flip side, Zepbound, much like Wegovy derived from Ozempic, is positioned in the market primarily as a weight management solution in the United States. Despite being pharmacologically identical to Mounjaro, Zepbound is dosed and marketed differently, focusing on its capacity to aid in significant weight reduction. Clinical trials supporting Zepbound’s approval for weight management showcased substantial weight loss in participants, further cementing GLP-1 receptor agonists' role in obesity treatment.
The parallel between Zepbound/Mounjaro and Ozempic/Wegovy is striking.
Ozempic, initially approved for managing diabetes, shares the same active ingredient as Wegovy, which is approved for weight management. The key difference lies in the dosing and the target audience, with Wegovy being prescribed at higher doses specifically for those looking to lose weight. This strategic bifurcation allows pharmaceutical companies to address two burgeoning health crises with a single molecule, maximizing the therapeutic potential of their discovery.
Clinical trials have been pivotal in demonstrating the efficacy of these medications. For instance, Mounjaro's phase 3 trials for diabetes management showed not only significant reductions in A1C levels but also noted weight loss as a side effect. Similarly, trials for Zepbound in the context of weight management have reported average weight losses of up to 26% of body weight in patients, offering a new hope for individuals struggling with weight issues.
As seen in
As seen in
Discreet packaging
Free, next-day delivery
Free cancellation
Full refund if ineligible
Discreet
packaging
Free, next-day delivery
Free
cancellation
Full refund if ineligible